false
0001812173
0001812173
2024-11-12
2024-11-12
0001812173
RBOT:ClassCommonStockParValue0.0001PerShareMember
2024-11-12
2024-11-12
0001812173
RBOT:WarrantsToPurchaseOneShareOfClassCommonStockEachAtExercisePriceOf11.50PerShareMember
2024-11-12
2024-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 12, 2024
VICARIOUS SURGICAL INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-39384 |
|
87-2678169 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
78 Fourth Avenue |
|
|
Waltham, Massachusetts |
|
02451 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (617) 868-1700
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
Class A common stock, par value $0.0001 per share |
|
RBOT |
|
The New York Stock Exchange |
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share |
|
RBOT WS |
|
The New York Stock Exchange |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
On November 12, 2024, Vicarious Surgical Inc.
(the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2024 and providing
a business update.
A copy of the press release issued on November
12, 2024 is furnished as Exhibit 99.1 hereto.
The information in this Current Report on Form
8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
VICARIOUS SURGICAL INC. |
|
|
|
|
By: |
/s/ Adam Sachs |
|
Name: |
Adam Sachs |
|
Title: |
Chief Executive Officer |
Date: November 12, 2024
2
Exhibit 99.1
Vicarious Surgical Reports Third Quarter 2024
Financial Results
WALTHAM, Mass.-- (BUSINESS WIRE) – November 12, 2024 –
Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics
technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended September
30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, November
12, 2024.
“Our team’s strong execution throughout
the year, continuing in the third quarter, has us on track to achieve our Version 1.0 System integration milestone within the next few
weeks,” said Adam Sachs, Co-Founder and Chief Executive Officer. “This sets the stage for us to complete our first clinical
patient in less than a year, a critical step that we believe will demonstrate the immense clinical value of our single-port robotic system
for both patients and surgeons.”
Third
Quarter 2024 Financial Results
| ● | Operating expenses were $17.8 million for the third quarter of 2024, compared to $21.4 million in the
corresponding prior year period, a decrease of 17%. |
| ● | R&D expenses for the third quarter of 2024 were $10.8 million, compared to $13.0 million in the third
quarter of 2023. |
| ● | General and administrative expenses for the third quarter of 2024 were $5.7 million, compared to $6.9
million in the third quarter of 2023. |
| ● | Sales and marketing expenses for the third quarter of 2024 were $1.2 million, compared to $1.4 million
in the third quarter of 2023. |
| ● | Adjusted net loss for the third quarter was $17.0 million, equating to a loss of $2.87 per share, as compared
to an adjusted net loss of $20.4 million, or a loss of $3.95 per share, for the same period of the prior year. GAAP net loss for the third
quarter was $17.1 million, equating to a net loss per share of $2.90, as compared to a GAAP net loss of $15.7 million or a net loss per
share of $3.04 for the same period of the prior year. |
| ● | The Company had $60.9 million of cash and investments as of September 30, 2024. The Company’s cash
burn rate for the third quarter of 2024 was $12.4 million. |
Full Year 2024 Cash Burn Guidance
| ● | Vicarious Surgical reiterates expected full year 2024 cash burn of approximately $50 million. |
Conference Call
Vicarious Surgical will host
a conference call today, Tuesday, November 12, 2024, at 4:30 p.m. ET to discuss its third quarter 2024 financial results. The call may
be accessed through an operator by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using
access code: 246564. A live and archived webcast of the event will be available at https://investor.vicarioussurgical.com.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company,
developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving
patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots
to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of
technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s
Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15
VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
Use of Non-GAAP Financial Measures
In addition to providing financial measurements
that have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”),
Vicarious Surgical provides additional financial metrics that are not prepared in accordance with U.S. GAAP (“non-GAAP”).
The non-GAAP financial measures included in this press release are Adjusted Net Loss and Adjusted Net Loss Per Share (“Adjusted
EPS”, and together with Adjusted Net Loss, “Non-GAAP Financial Measures”). The Company presents Non-GAAP Financial Measures
in order to assist readers of its consolidated financial statements in understanding the core operating results that its management uses
to evaluate the business and for financial planning purposes. Vicarious Surgical’s Non-GAAP financial measures provide an additional
tool for investors to use in comparing its financial performance over multiple periods.
Adjusted Net Loss and Adjusted EPS are key performance
measures that Vicarious Surgical’s management uses to assess its operating performance. These Non-GAAP Financial Measures facilitate
internal comparisons of Vicarious Surgical’s operating performance on a more consistent basis. Vicarious Surgical uses these performance
measures for business planning purposes and forecasting. Vicarious Surgical believes that the Non-GAAP Financial Measures enhance an investor’s
understanding of Vicarious Surgical’s financial performance as it is useful in assessing its operating performance from period-to-period
by excluding certain items that Vicarious Surgical believes are not representative of its core business.
The Non-GAAP Financials Measures may not be comparable
to similarly titled measures of other companies because they may not calculate this measure in the same manner. Adjusted Net Loss and
Adjusted EPS are not prepared in accordance with U.S. GAAP and should not be considered in isolation of, or as an alternative to, measures
prepared in accordance with U.S. GAAP. When evaluating Vicarious Surgical’s performance, you should consider the Non-GAAP Financial
Measures alongside other financial performance measures prepared in accordance with U.S. GAAP, including net loss.
The Non-GAAP Financial Measures do not replace
the presentation of Vicarious Surgical’s U.S. GAAP financial results and should only be used as a supplement to, not as a substitute
for, Vicarious Surgical’s financial results presented in accordance with U.S. GAAP. In this press release, Vicarious Surgical has
provided a reconciliation of Adjusted Net Loss to net loss, the most directly comparable U.S. GAAP financial measure, and the calculation
for Adjusted EPS.
Forward-Looking Statements
This press release includes “forward-looking
statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform
Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should
not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts
contained herein, including without limitation the quotations of our Chief Executive Officer regarding Vicarious Surgical’s opportunity,
timeline for achieving our Version 1.0 System integration and timeline for completing our first clinical patient, among other things,
are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve
significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking
statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause
such differences include, but are not limited to: the ability to maintain the listing of Vicarious Surgical’s Class A common stock
on the New York Stock Exchange; the approval, commercialization and adoption of Vicarious Surgical’s initial product candidates
and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and
service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the
success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits
of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval
for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human
clinical trials for the Vicarious Surgical System; Vicarious Surgical’s ability to identify, in-license or acquire additional technology;
Vicarious Surgical’s ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical’s
ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical
is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical’s product candidates and
services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical’s
product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s
estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical’s financial performance;
economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial
condition and results of operations; Vicarious Surgical’s intellectual property rights and its ability to protect or enforce those
rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties
indicated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of
factors is not exclusive. The company cautions readers not to place undue reliance upon any forward-looking statements, which speak only
as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances
on which any such statement is based.
VICARIOUS SURGICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except share and per share data)
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Operating expenses: | |
| | |
| | |
| | |
| |
Research and development | |
$ | 10,800 | | |
$ | 13,040 | | |
$ | 31,692 | | |
$ | 39,110 | |
Sales and marketing | |
| 1,208 | | |
| 1,401 | | |
| 3,546 | | |
| 5,027 | |
General and administrative | |
| 5,747 | | |
| 6,911 | | |
| 16,339 | | |
| 20,988 | |
Total operating expenses | |
| 17,755 | | |
| 21,352 | | |
| 51,577 | | |
| 65,125 | |
Loss from operations | |
| (17,755 | ) | |
| (21,352 | ) | |
| (51,577 | ) | |
| (65,125 | ) |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Change in fair value of warrant liabilities | |
| (138 | ) | |
| 4,703 | | |
| (415 | ) | |
| 3,705 | |
Interest and other income | |
| 802 | | |
| 946 | | |
| 2,695 | | |
| 3,463 | |
Interest expense | |
| — | | |
| (1 | ) | |
| — | | |
| (3 | ) |
Income/(loss) before income taxes | |
| (17,091 | ) | |
| (15,704 | ) | |
| (49,297 | ) | |
| (57,960 | ) |
Provision for income taxes | |
| — | | |
| — | | |
| — | | |
| — | |
Net income/(loss) | |
$ | (17,091 | ) | |
$ | (15,704 | ) | |
$ | (49,297 | ) | |
$ | (57,960 | ) |
Net income/(loss) per share of Class A and Class B common stock, basic | |
$ | (2.90 | ) | |
$ | (3.04 | ) | |
$ | (8.39 | ) | |
$ | (12.77 | ) |
Weighted average shares, diluted | |
| 5,899,616 | | |
| 5,171,380 | | |
| 5,876,626 | | |
| 4,539,806 | |
Other comprehensive income/(loss): | |
| | | |
| | | |
| | | |
| | |
Net unrealized gain/(loss) on investments | |
| 175 | | |
| 41 | | |
| 114 | | |
| (89 | ) |
Other comprehensive gain/(loss) | |
| 175 | | |
| 41 | | |
| 114 | | |
| (89 | ) |
Comprehensive net income/(loss) | |
$ | (16,916 | ) | |
$ | (15,663 | ) | |
$ | (49,183 | ) | |
$ | (58,049 | ) |
VICARIOUS SURGICAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except share and per share data)
| |
September 30, | | |
December 31, | |
| |
2024 | | |
2023 | |
Assets | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 7,069 | | |
$ | 52,822 | |
Short-term investments | |
| 53,795 | | |
| 45,355 | |
Prepaid expenses and other current assets | |
| 3,113 | | |
| 2,776 | |
Total current assets | |
| 63,977 | | |
| 100,953 | |
Restricted cash | |
| 936 | | |
| 936 | |
Property and equipment, net | |
| 4,820 | | |
| 6,402 | |
Right-of-use assets | |
| 10,794 | | |
| 11,459 | |
Other long-term assets | |
| 89 | | |
| 114 | |
Total assets | |
$ | 80,616 | | |
$ | 119,864 | |
| |
| | | |
| | |
Liabilities, Convertible Preferred Stock and Stockholders’ Equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 2,416 | | |
$ | 1,258 | |
Accrued expenses | |
| 5,013 | | |
| 4,975 | |
Lease liabilities, current portion | |
| 1,174 | | |
| 1,047 | |
Total current liabilities | |
| 8,603 | | |
| 7,280 | |
Lease liabilities, net of current portion | |
| 12,886 | | |
| 13,785 | |
Warrant liabilities | |
| 1,245 | | |
| 830 | |
Total liabilities | |
| 22,734 | | |
| 21,895 | |
Stockholders’ equity: | |
| | | |
| | |
Class A Common Stock | |
| 15 | | |
| 15 | |
Class B Common Stock | |
| 2 | | |
| 2 | |
Additional paid-in capital | |
| 239,750 | | |
| 230,654 | |
Accumulated other comprehensive income | |
| 124 | | |
| 10 | |
Accumulated deficit | |
| (182,009 | ) | |
| (132,712 | ) |
Total stockholders’ equity | |
| 57,882 | | |
| 97,969 | |
Total liabilities and stockholders’ equity | |
$ | 80,616 | | |
$ | 119,864 | |
VICARIOUS SURGICAL INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL
MEASURES
(in thousands, except share and per share data)
Adjusted net loss and Adjusted EPS
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Net income/(loss) | |
$ | (17,091 | ) | |
$ | (15,704 | ) | |
$ | (49,297 | ) | |
$ | (57,960 | ) |
Change in fair value of warrant liabilities | |
| (138 | ) | |
| 4,703 | | |
| (415 | ) | |
| 3,705 | |
Adjusted net loss | |
| (16,953 | ) | |
| (20,407 | ) | |
| (48,882 | ) | |
| (61,665 | ) |
Adjusted EPS, basic and diluted | |
$ | (2.87 | ) | |
$ | (3.95 | ) | |
$ | (8.32 | ) | |
$ | (13.58 | ) |
Weighted average shares, basic and diluted | |
| 5,899,616 | | |
| 5,171,380 | | |
| 5,876,626 | | |
| 4,539,806 | |
Investor Contact
Kaitlyn Brosco
Vicarious Surgical
Kbrosco@vicarioussurgical.com
Media Inquiries
media@vicarioussurgical.com
23076573v.1
v3.24.3
Cover
|
Nov. 12, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 12, 2024
|
Entity File Number |
001-39384
|
Entity Registrant Name |
VICARIOUS SURGICAL INC.
|
Entity Central Index Key |
0001812173
|
Entity Tax Identification Number |
87-2678169
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
78 Fourth Avenue
|
Entity Address, City or Town |
Waltham
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02451
|
City Area Code |
617
|
Local Phone Number |
868-1700
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Class A common stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Class A common stock, par value $0.0001 per share
|
Trading Symbol |
RBOT
|
Security Exchange Name |
NYSE
|
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share |
|
Title of 12(b) Security |
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
|
Trading Symbol |
RBOT WS
|
Security Exchange Name |
NYSE
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=RBOT_ClassCommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=RBOT_WarrantsToPurchaseOneShareOfClassCommonStockEachAtExercisePriceOf11.50PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Vicarious Surgical (NYSE:RBOT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Vicarious Surgical (NYSE:RBOT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024